COMMUNIQUÉS West-GlobeNewswire

ContraVir Pharmaceuticals to Present at NobleCon14
23/01/2018
EDISON, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced [...]
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events
23/01/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Orion to investigate possible sale of Orion Diagnostica
23/01/2018
ORION CORPORATION STOCK EXCHANGE RELEASE 23 JANUARY 2018 at 12.20. p.m. EET Orion to investigate possible sale of Orion Diagnostica Orion Corporation has evaluated strategic alternatives of the Group's Orion Diagnostica [...]
NE Indiana Urology Partnering with UroChoice™ for Technology Needs
23/01/2018
INDIANAPOLIS, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Northeast Indiana Urology, a team of 14 board-certified clinicians specializing in adult men’s and women’s urological care maintain more than 70 staff members over 11 [...]
Nexstim Plc receives R&D loan from Business Finland
23/01/2018
Company announcement, Helsinki, 23 January 2018, at 10:00 a.m. Nexstim Plc receives R&D loan from Business Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing [...]
GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
23/01/2018
GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA FDA (Food and Drug Administration) agrees with elafibranor's initial Pediatric Study Plan (PSP) for the launch of a [...]
GENFIT : Lancement officiel du programme pédiatrique dans la NASH suite à l'accord de l'EMA et de la FDA sur les PIP et PSP
23/01/2018
GENFIT : Lancement officiel du programme pédiatrique dans la NASH suite à l'accord de l'EMA et de la FDA sur les PIP et PSP La FDA (Food and Drug Administration) accepte le plan initial d'étude pédiatrique (PSP) pour le [...]
Invitation C-RAD Web Presentation Year-end Report 2017
23/01/2018
Press release 2018-01-23 C-RAD Web Presentation Year-end Report 2017 Presentation of the report for the fiscal year 2017: Date: Thursday January 31, 2018 / kl. 11:00 Venue: Online Presentation Topic: C-RAD Year-end [...]
New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)
23/01/2018
Company announcement - No. 5/2018 New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS) Zealand has completed a pharmacokinetic (PK) study with glepaglutide that [...]
TLC and Jixi Biotechnology Partners Announce Joint Venture
23/01/2018
TAIPEI, Taiwan, Jan. 23, 2018 (GLOBE NEWSWIRE) -- TLC (4152.TT) today announced that it has signed an agreement with Jixi Biotechnology Partners to form a joint venture in TLC Biopharmaceuticals (H.K.) Limited (TLCHK) [...]
Bone Therapeutics SA : Provides business outlook and announces its financial calendar for 2018
23/01/2018
Regulated information Bone Therapeutics provides business outlook and announces its financial calendar for 2018 Completion of recruitment in its Phase IIA spinal fusion trial with ALLOB ® , following positive interim [...]
Bone Therapeutics SA : Publie ses perspectives d'affaires et annonce son calendrier financier pour 2018
23/01/2018
Information réglementée Bone Therapeutics publie ses perspectives d'affaires et annonce son calendrier financier pour 2018 Achèvement du recrutement de l'essai de Phase IIA dans la fusion vertébrale avec ALLOB ® attendu [...]
AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
23/01/2018
TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for [...]
Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
23/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA ) today announced that an abstract detailing interim results from the Company’s ongoing Phase 3b/4 trial of [...]
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
23/01/2018
WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX ), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten [...]
Pacific Biosciences of California, Inc. Fourth Quarter and Year-End 2017 Financial Results Call
22/01/2018
MENLO PARK, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB ) will hold its quarterly conference call to discuss its Fourth Quarter and Year-End 2017 Financial Results on [...]
ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
22/01/2018
-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients -- -- Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium -- MOUNTAIN VIEW, Calif., [...]
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
22/01/2018
LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options The trial met its primary [...]
Ultragenyx Announces Proposed Public Offering of Common Stock
22/01/2018
NOVATO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today [...]

Pages